Physiomics - Virtual Tumour™
Physiomics has developed a proprietary modelaided simulation of tumours, Virtual Tumour™, to help pharmaceutical companies improve the success rate of drug development.
Find your nearest AHSN
Virtual Tumour™ works by predicting the effects of cancer treatment regimes, simulating the growth or shrinkage of tumours under the effects of any combination of anti-cancer agents.
The company wants to expand the utility of this technology by exploring methods of personalising oncology treatments and dosages for patients.
The Oxford AHSN has provided us with feedback from medical oncologists and been a gateway into the NHS. Market access has been paramount in the adoption of the personalised dosing app and has enabled us to speak to clinicians we otherwise would not have had access to.
Jim Millen, Chief Executive Officer, Physiomics
How did the Innovation Exchange help?
Physiomics has partnered with Oxford AHSN as well as clinicians at Oxford University Hospitals to explore the utility of the technology in different tumour types. This work was facilitated by two Innovate UK grants. The first (£131,000) was focused on oesophageal cancer, while the second was for prostate cancer (£68,000). Both grants provided funding for Physiomics to develop the Virtual Tumour™ technology for the two cancer types.
The Oxford AHSN led feasibility studies to determine the utility of the technology in a clinical setting. In the first study, the Oxford AHSN conducted its Lean Assessment Process into a decision support tool in oesophageal cancer. The second was a stakeholder engagement study for a personalised dosing app for prostate cancer. In both cases stakeholders were interviewed, results analysed and fed back to Physiomics in order to refine their future product development.